modelBlinatumomab
Extends from Pharmacolibrary.Drugs.ATC.L.L01FX07.
Information
| name: | Blinatumomab | |
| ATC code: | L01FX07 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 28 | mg |
| volume of distribution: | 4.35 | L |
| clearance: | 2.92 | L/h |
| other parameters in model implementation | ||
Blinatumomab is a bispecific T-cell engager (BiTE) monoclonal antibody used in the treatment of acute lymphoblastic leukemia (ALL). It binds CD19 on B-cells and CD3 on T-cells, directing cytotoxic T-cells to kill malignant B-cells. Blinatumomab is approved for the treatment of relapsed or refractory B-cell precursor ALL in adults and children.
Pharmacokinetics
Pharmacokinetic parameters reported in adults (18–77 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia treated with intravenous blinatumomab. Parameters obtained at steady-state during continuous intravenous infusion.
References
Clements, JD, et al., & Doshi, S (2020). Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. Clinical pharmacokinetics 59(4) 463–474. DOI:10.1007/s40262-019-00823-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31679130
Zhu, M, et al., & Doshi, S (2016). Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clinical pharmacokinetics 55(10) 1271–1288. DOI:10.1007/s40262-016-0405-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27209293
Kaplan, JB, et al., & Giles, FJ (2015). Blinatumomab for the treatment of acute lymphoblastic leukemia. Investigational new drugs 33(6) 1271–1279. DOI:10.1007/s10637-015-0289-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26383529
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)